



MAR 14 2002

TECH CENTER 1600/2900

PATENT

Attorney Docket No. 29666/35415

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

8/B w/att  
clm  
2-19-02

Applicants:	)	I hereby certify that this paper is being	2-19-02
	)	deposited with the United States Postal	
Williams <i>et al.</i>	)	Service as first class mail, postage prepaid,	
	)	in an envelope addressed to:	
Serial No. 09/529,053	)	Assistant Commissioner for Patents,	Be
	)	Washington, DC 20231 on this date:	3-22-02
Filed: April 6, 2000	)	February 19, 2002	
	)		
For: Anti-Viral Uses of	)		
Leflunomide Products	)		
	)		
Group Art Unit: 1617	)		
	)		
Examiner: S. Wang	)	Michael F. Borun, Reg. No. 25,447	
	)	Attorney for Applicants	

APPLICANTS' REPLY, AMENDMENT, AND REQUEST  
FOR RECONSIDERATION PURSUANT TO 37 C.F.R. §1.111

Assistant Commissioner for Patents  
Washington, DC 20231

Sir:

This is in response to the Office Action dated October 17, 2001, wherein:

(a) the outstanding restriction requirement was made final despite traversal by Applicants; and,

(b) provisionally elected claims 1-13 were variously objected to and rejected under 35 U.S.C. §§ 112, second paragraph, 102(b) and 103(a). Reconsideration and allowance is requested by view of the following Amendments and remarks